Faecal Immunochemical Testing for NHS Shropshire, Telford and Wrekin Clinical Commissioning Group

Concepts

• telford
• wrekin clinical commissioning group
• health services
• nhs shropshire
• faecal immunochemical testing
• soft market testing
• commissioning of a faecal immunochemical test
• nhs long term plan
• clinical commissioning groups
• future commissioning

Location

Description

This is an advertisement for soft market testing to gauge market interest which will influence future commissioning and procurement direction. NHS Shropshire , Telford and Wrekin Clinical Commissioning Group (STW CCG) are looking to seek expressions of interest and to engage with the market with regards to the commissioning of a Faecal Immunochemical Test (FIT) service which will include both 2 week wait and non 2 week wait (2WW) activity in line with NICE NG12 guidance. The service is requested by Primary Care and there is the requirement to communicate results directly to the secondary care service at Shrewsbury and Telford NHS Trust. The service includes the supply of tests, analysis of samples and communicating the results. This in line with the requirements of the: - NHS Long Term Plan (2019) to achieve the target set around diagnosing 75% of cancers at an earlier stage and ensuring 55,000 more people survive for at least 5 years after diagnosis by 2028. - NHS 2022/23 priorities and operational planning guidance 2021 to ensure the provision of sufficient commissioned capacity that every urgent suspected lower GI cancer referral is accompanied by a (FIT) result. STW CCG is committed to develop and deliver world class outcomes in Cancer care and treatment for the population. This ambitious plan requires local health care systems to work collaboratively to implement changes which will bring about significant improvements in the lives of people diagnosed with cancer and enable more people to live full lives beyond cancer. Currently more than 385,000 people in the UK are diagnosed with cancer each year - Approximately 3,570 people in Shropshire, Telford & Wrekin are diagnosed with cancer each year - There is an estimated 50,000 people living with and beyond cancer in Shropshire, Telford & Wrekin and this is predicted to rise - Macmillan estimate there are 3 million people living with cancer and this is set to increase to 4 million by 2023, and 5.3 million by 2040 It is envisaged that this service would be live for the period of 3 years with the option to extend up to a period of 24 month. The approximate overall value is £900,000.00 (approx. £180,000.00 per annum). To register your Expression of Interest (EOI) and to complete the engagement questionnaire please visit the Midlands and Lancashire Bravo e-tendering portal: https://mlcsu.bravosolution.co.uk. Bravo reference pqq_509. The closing date for EOIs is 12:00 noon on Tuesday 19th July 2022. Please note as of the 1st July 2022 Clinical Commissioning Groups will become Integrated Care Boards.

CPV Codes

• 85100000 - Health services
• 85145000 - Services provided by medical laboratories

Indicators

• Contract is suitable for SMEs.

Other Information

It should be noted that this is not a procurement exercise at this stage and participating organisations are responsible for their own costs. To register your Expression of Interest (EOI) and or provide feedback/complete the engagement questionnaire please visit the Midlands and Lancashire Bravo e-tendering portal: https://mlcsu.bravosolution.co.uk, pqq_509. The closing date for EOIs and feedback is 12:00 noon on the Tuesday 19th July 2022. This future procurement is for Light Touch Regime services for the purpose of the Public Contracts Regulations 2015 as specified in Schedule 3 of the Regulations ("Regulations"). Accordingly, the Contracting Authorities are only bound by those parts of the Regulations detailed in Chapter 3 Particular Procurement Regimes Section 7. The Contracting Authorities are not voluntarily following any other part of the regulations. The CCG is a relevant body for the purpose of the National Health Service (procurement, patient choice and competition) (No. 2) Regulations 2013. MLCSU Bravo eTendering Portal https://mlcsu.bravosolution.co.uk